Menu
Curie Logo
Donate
  • Home

Clinical trials - page 3

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Paris
    MCLA-158-CL02
    A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma

    EDITH BORCOMAN

  • ENT/Head and Neck Cancers
    Paris
    MCLA-158-CL03/LiGeR-HN1
    A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

    CHRISTOPHE LE TOURNEAU

  • Childhood and adolescent cancers
    Paris
    iMATRIX-Alectinib (GO42286)
    A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.

    FRANCOIS DOZ

  • Paris
    EGL-001 (EGL-121)
    First-in-human Trial of EGL-001 in Patients with Selected Advanced And/·or Metastatic Solid Tumors

    EDITH BORCOMAN

  • Paris, Saint-Cloud
    TUMOSPEC (ONCO04) - Paris
    Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

    DOMINIQUE STOPPA-LYONNET

  • Childhood and adolescent cancers
    Paris
    INFORM2 - NIVENT (IC 2018-07)
    INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies

    GUDRUN SCHLEIERMACHER

  • Lung cancer
    Paris
    BAYER 22615 (SOHO 02)
    A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations.

    NICOLAS GIRARD

  • Digestive cancers
    Paris, Saint-Cloud
    ProActIF-01
    ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers

    TIMOTHEE MARCHAL

  • Lymphoma
    Saint-Cloud
    CA073-1020
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

    CLEMENTINE SARKOZY

  • Hématologie / cancers du sang
    Saint-Cloud
    CA073-1022
    Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced-Stage Follicular Lymphoma (GOLSEEK-2)"

    CLEMENTINE SARKOZY

  • Breast cancer
    Saint-Cloud
    CAAA603B12101 NeoB
    Phase Ib Dose Finding Study Assessing Safety and Activity;of [;177Lu]LuNeob in combination with ribocilcib and fulvestrant;in subjects with HR positive, HER2 negative breast cancer,;experiencing early relapse from (neo)adjuvant endocrine;therapy.

    CAPUCINE RICHARD

  • Cancers urogénitaux
    Paris, Saint-Cloud
    CAAA617D12302
    A prospective, multicenter, open-label, randomized international Phase III study evaluating treatment with lutetium (177Lu) vipivotide tetraxetan (AAA617) versus surveillance alone to delay the need for castration or disease recurrence in adult male patients with PSMA-positive oligometastatic prostate cancer.

    CAPUCINE RICHARD

  • Saint-Cloud
    CANTO (Saint-Cloud)
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer

    FLORENCE LEREBOURS

  • Saint-Cloud
    CANTO BIS
    A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer.

    FLORENCE LEREBOURS

  • Breast cancer
    Paris, Saint-Cloud
    CAPPA
    Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery (CAPPA).

    DELPHINE LOIRAT

  • Paris
    CINNAMON
    Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial.

  • Digestive cancers
    Saint-Cloud
    CL1-95029-002
    Open-label, non-randomized, Phase 1b/2 trial investigating the;safety, tolerability, and antitumor activity of S095029 (anti-;NKG2A antibody) as a part of combination therapy in participants;with locally advanced and unresectable or metastatic MSIH/;dMMR gastroesophageal junction /gastric cancer

  • Paris
    CLEVER-PEPTIDE (IC 2018-06)
    Open-label, non-controlled, multicenter, dose escalation, first-in-human phase I clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer.

    CHRISTOPHE LE TOURNEAU

  • Tumeurs du système nerveux central
    Paris, Saint-Cloud
    COG-PROTON-01
    Long-term cognitive and functional impact of proton-therapy or modern fractionated radiotherapy in cavernous sinus meningioma: An open-label randomized 1:1 phase III study

    EMMANUEL JOUGLAR, MAXIME LOO

  • Saint-Cloud
    CONTESSA - ODO-TE-B301
    Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

    ETIENNE BRAIN

  • Lung cancer
    Paris
    CONVERGE
    A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in;combination with chemoradiation followed by durvalumab in locally advanced and;unresectable Stage III non-small cell lung cancer

    NICOLAS GIRARD

  • Childhood and adolescent cancers
    Paris
    CRISP (IC 2017-08 / ITCC 053)
    A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies.

    ISABELLE AERTS GAJDOS

  • Breast cancer
    Saint-Cloud
    CT7001_003 (SUMIT ELA)
    A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    CodeBreak202
    A Phase 3, Multicenter, Randomized, Open-label;Study Evaluating Efficacy of Sotorasib Platinum;Doublet Combination Versus Pembrolizumab;Platinum Doublet Combination as a Front-Line;Therapy in Subjects With Stage IV or Advanced;Stage IIIB/C Nonsquamous NonÀSmall Cell Lung;Cancers, Negative for PD-L1, and Positive for;KRAS p.G12C (CodeBreaK 202)

    NICOLAS GIRARD

  • Saint-Cloud
    D7407C00001- SOUNDTRACK-E
    A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies (Soundtrack-E).

    CLEMENTINE SARKOZY

  • Saint-Cloud
    DOLAF
    An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib

  • Cancers gynécologiques
    Saint-Cloud
    DS6000-109
    A Phase 2/3, Multicenter, Randomized Study of Raludotatug;Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate,;in Subjects with Platinum-resistant, High-grade Ovarian, Primary;Peritoneal, or Fallopian Tube Cancer.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    DS8201-A-U207 DESTINY CRC02
    A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)

  • Cancers gynécologiques
    Saint-Cloud
    E7386-J081-102_(PENT-02)
    An Open-Label Study of E7386 in Combination With Other;Anticancer Drug(s) in Subjects With Solid Tumors.

    DIANA BELLO ROUFAI

  • Saint-Cloud
    EMBER-2 (J2J-MC-JZLB)
    EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer.

    FRANCOIS-CLEMENT BIDARD

<
1 ...3...7
>